{"id":"igiv-c-10","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Aseptic meningitis"}]},"_chembl":{"chemblId":"CHEMBL5907109","moleculeType":null,"molecularWeight":"527.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IGIV-C is a polyclonal immunoglobulin G (IgG) product derived from pooled human plasma that contains a broad spectrum of antibodies. It functions through multiple mechanisms including opsonization of pathogens, complement activation, Fc receptor engagement, and immune modulation to treat primary immunodeficiencies and autoimmune/inflammatory conditions. The 10% concentration allows for higher-dose administration with reduced infusion volumes.","oneSentence":"IGIV-C 10% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:32.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency conditions"},{"name":"Autoimmune and inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":"Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies","enrollment":13},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04578535","phase":"PHASE1","title":"A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2020-10-27","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":"Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy","enrollment":20},{"nctId":"NCT04561115","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-02","conditions":"Primary Immunodeficiency","enrollment":33},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT04480424","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-17","conditions":"COVID-19","enrollment":100},{"nctId":"NCT02413580","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-03","conditions":"Myasthenia Gravis Exacerbations","enrollment":49},{"nctId":"NCT02604810","phase":"PHASE3","title":"Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2016-01","conditions":"Primary Immunodeficiency","enrollment":53},{"nctId":"NCT01854827","phase":"PHASE1, PHASE2","title":"Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-10","conditions":"Biliary Atresia","enrollment":30},{"nctId":"NCT02473952","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-08","conditions":"Myasthenia Gravis, Generalized","enrollment":62},{"nctId":"NCT01804829","phase":"PHASE3","title":"Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.","status":"COMPLETED","sponsor":"Biotest Pharmaceuticals Corporation","startDate":"2013-06","conditions":"Hepatitis C Infection, Viruses, Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT00090194","phase":"PHASE2","title":"Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06","conditions":"Kidney Failure, Chronic","enrollment":56},{"nctId":"NCT00220727","phase":"PHASE2","title":"Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2003-07","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":8},{"nctId":"NCT00220779","phase":"PHASE2","title":"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":128},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":117},{"nctId":"NCT00220805","phase":"PHASE2","title":"Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-01","conditions":"Macular Degeneration","enrollment":96},{"nctId":"NCT00389324","phase":"PHASE2","title":"A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2006-11","conditions":"Immunologic Deficiency Syndrome","enrollment":35},{"nctId":"NCT01465958","phase":"PHASE4","title":"Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2011-11","conditions":"Primary Immunodeficiency","enrollment":12},{"nctId":"NCT00606905","phase":"NA","title":"Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage","status":"COMPLETED","sponsor":"University of Chicago","startDate":"1999-11","conditions":"Miscarriage, Recurrent, Abortion, Habitual","enrollment":82},{"nctId":"NCT00220766","phase":"PHASE3","title":"Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-08","conditions":"Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune Globulin Injection 10% Caprylate/Chromatography"],"phase":"phase_3","status":"active","brandName":"IGIV-C 10%","genericName":"IGIV-C 10%","companyName":"Grifols Therapeutics LLC","companyId":"grifols-therapeutics-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"IGIV-C 10% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency conditions, Autoimmune and inflammatory disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}